Enlivex Therapeutics/$ENLV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enlivex Therapeutics
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Ticker
$ENLV
Sector
Primary listing
Employees
-
Headquarters
Ness Ziona, Israel
Website
ENLV Metrics
BasicAdvanced
$254M
-
-$0.54
1.59
-
Price and volume
Market cap
$254M
Beta
1.59
52-week high
$2.10
52-week low
$0.66
Average daily volume
285K
Financial strength
Current ratio
6.433
Quick ratio
6.256
Long term debt to equity
2.437
Total debt to equity
4.01
Profitability
EBITDA (TTM)
-14.328
Management effectiveness
Return on assets (TTM)
-36.02%
Return on equity (TTM)
-57.64%
Valuation
Price to book
1.49
Price to tangible book (TTM)
1.49
Price to free cash flow (TTM)
-2.105
Free cash flow yield (TTM)
-47.51%
Free cash flow per share (TTM)
-0.508
Growth
Earnings per share change (TTM)
-44.36%
3-year earnings per share growth (CAGR)
-29.80%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enlivex Therapeutics stock?
Enlivex Therapeutics (ENLV) has a market cap of $254M as of March 14, 2026.
What is the P/E ratio for Enlivex Therapeutics stock?
The price to earnings (P/E) ratio for Enlivex Therapeutics (ENLV) stock is 0 as of March 14, 2026.
Does Enlivex Therapeutics stock pay dividends?
No, Enlivex Therapeutics (ENLV) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next Enlivex Therapeutics dividend payment date?
Enlivex Therapeutics (ENLV) stock does not pay dividends to its shareholders.
What is the beta indicator for Enlivex Therapeutics?
Enlivex Therapeutics (ENLV) has a beta rating of 1.59. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.